Novo Nordisk signs deal with OpenAI to develop new drugs

Copenhagen, Apr 14, 2026 -

Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a "strategic partnership" with OpenAI to accelerate the development of new medications.

Novo Nordisk said the partnership would place it "at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster".


No financial details of the partnership were disclosed.